

10/035,100

-2-

00378.US1
PC024976REMARKS

Claims 1, 3, 4, 7-9, 11-13, 15-16, and 18 remain in the application. Only Claims 1, 9, and 18 are in independent form.

Claims 1, 3, 4, 7-9, 11-13, 15-16, and 18 stand rejected under 35 U.S.C. § 103(a) as allegedly be unpatentable over Bymaster, et al., EP 0830864 (hereinafter referred to "Bymaster").

As stated in the Office Action, Bymaster teaches combination compositions comprising an atypical antipsychotic agent and a serotonin reuptake inhibitor and the therapy for treatment of schizophrenia. See, page 12, lines 50-51, as well as the various combinations at the bottom of page 3. The claims differ in that Bymaster does not recite the serotonin reuptake inhibitor reboxetine. Applicants respectfully submit that reboxetine is a well known norepinephrine reuptake inhibitor (as stated on page 1, lines 15-16) rather than a serotonin reuptake inhibitor as taught in "Bymaster". Since "Bymaster" only teaches the combination of atypical antipsychotic with a serotonin reuptake inhibitor, Applicants submit that "Bymaster" does not render obvious the presently claims invention. Accordingly, Applicants respectfully request reconsideration of the presently pending rejection.

In view of the present amendment and foregoing remarks, reconsideration of the rejection and advance of the case to issue are respectfully requested.

10/035,100

-3-


00378.US1

PC024976

The Commissioner is authorized to charge any fee or credit any overpayment in connection with the communication to our deposit account number 23-0455.

Dated: 7/19/04

Respectfully submitted,



David R. Kurlandsky
Registration No. 41,505
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105
Telephone: (734) 622-7304
Facsimile: (734) 622-1553

DRK 24976 US Response 7-16-2004